Mehmet Ay

Canakkale, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

New 3H-1,2-Dithiole-3-thione derivatives: Design and synthesis, H2S-release profile, in vitro anticancer activity, and in silico multi-target assessment.

New 3H-1,2-Dithiole-3-thione derivatives: Design and synthesis, H2S-release profile, in vitro anticancer activity, and in silico multi-target assessment.

Journal: Molecular diversity

Published: May 01, 2026

Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2-Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple-Negative Breast Cancer Therapy and Structure-Activity Relationship.

Design, Synthesis, Biological Evaluation, and Molecular Modeling Studies of Novel 2-Aminothiazole Derivatives as Potential FOXM1 Inhibitors for Triple-Negative Breast Cancer Therapy and Structure-Activity Relationship.

Journal: Drug development research

Published: December 13, 2025

Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis.

Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis.

Journal: International journal of biological macromolecules

Published: November 10, 2025

Boron Containing Curcumin-Like Compound as an Acetylcholinesterase Inhibitor and Anticancer Agent: Synthesis, Biological Evaluation, and Computational Insights.

Boron Containing Curcumin-Like Compound as an Acetylcholinesterase Inhibitor and Anticancer Agent: Synthesis, Biological Evaluation, and Computational Insights.

Journal: Cell biochemistry and biophysics

Published: August 31, 2025

New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers.

New and potential boron-containing compounds for treatment of Alzheimer's disease and cancers.

Journal: Future medicinal chemistry

Published: July 02, 2025

Synthesis, in silico and bio-evaluation studies of new isothiocyanate derivatives with respect to COX inhibition and H2S release profiles.

Synthesis, in silico and bio-evaluation studies of new isothiocyanate derivatives with respect to COX inhibition and H2S release profiles.

Journal: RSC medicinal chemistry

Published: July 02, 2024

Novel benzothiazole/benzothiazole thiazolidine-2,4-dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies.

Novel benzothiazole/benzothiazole thiazolidine-2,4-dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies.

Journal: Archiv der Pharmazie

Published: June 19, 2024

A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells.

A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells.

Journal: Medical oncology (Northwood, London, England)

Published: April 21, 2024

Synthesis of new imine-/amine-bearing imidazo[1,2-a]pyrimidine derivatives and screening of their cytotoxic activity.

Synthesis of new imine-/amine-bearing imidazo[1,2-a]pyrimidine derivatives and screening of their cytotoxic activity.

Journal: Turkish journal of chemistry

Published: May 17, 2023

Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.

Novel etodolac derivatives as eukaryotic elongation factor 2 kinase (eEF2K) inhibitors for targeted cancer therapy.

Journal: RSC medicinal chemistry

Published: March 31, 2022

Identifying highly effective coumarin-based novel cholinesterase inhibitors by in silico and in vitro studies.

Identifying highly effective coumarin-based novel cholinesterase inhibitors by in silico and in vitro studies.

Journal: Journal of molecular graphics & modelling

Published: August 23, 2021

Correction to "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo".

Correction to "Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo".

Journal: ACS pharmacology & translational science

Published: April 17, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026